In select patients with HER2-negative breast cancer

gBRCAm testing is recommended by leading medical authorities14-16

NCCN Guidelines® Recommend

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend germline BRCA testing at any age for certain patients with a personal history of breast cancer to aid treatment decisions with PARP inhibitors, including olaparib

Treatment indications at any age:

  • To aid in systemic treatment decisions using PARP inhibitors for breast cancer in metastatic setting
  • To aid in adjuvant treatment decisions with olaparib for high-risk,* HER2-negative breast cancer

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*High-risk disease in patients with TNBC is defined as either 1) treated with adjuvant chemotherapy and with axillary node-positive disease or an invasive breast tumor ≥2 cm on pathology analysis or 2) treated with neoadjuvant chemotherapy and with residual invasive breast cancer in the breast or resected lymph nodes. High-risk disease in patients with HR-positive, HER2-negative disease is defined as either 1) treated with adjuvant chemotherapy and with ≥4 positive pathologically confirmed lymph nodes or 2) treated with neoadjuvant chemotherapy which did not have a complete pathologic response and with a CPS&EG score of ≥3.


ASCO-SSO® Guidelines Recommend†

gBRCA1/2 mutation testing should be offered to:

  • All patients newly diagnosed with breast cancer with stage I-III or de novo stage IV/metastatic disease who are 65 years or younger at diagnosis should be offered BRCA1/2 testing (Type: Formal Consensus; Agreement: 87.50%).
  • All patients newly diagnosed with breast cancer with stage I-III or de novo stage IV/metastatic disease who are older than age 65 should be offered BRCA1/2 testing if:
    • they are candidates for poly (ADP-ribose) polymerase (PARP) inhibitor therapy for early-stage or metastatic disease,
    • they have triple-negative breast cancer, their personal or family history suggests the possibility of a pathogenic variant,
    • they were assigned male sex at birth, they are of Ashkenazi Jewish ancestry, or are members of a population with an increased prevalence of founder mutations (Type: Formal Consensus; Agreement: 92.50%).

ASBrS® Guidelines Recommend

Genetic testing, including gBRCA1/2 mutation testing, should be made available to all patients with a personal history of breast cancer to help:

  • Inform treatment decisions, including surgery, potential radiotherapy, and systemic therapy
  • Assess hereditary risk

†The information in this brochure is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients.